Explore how non-viral mbDNA enables efficient gene editing in hematopoietic stem cells while preserving viability, engraftment, and long-term function—driving safer, scalable gene therapies.
Read More
Touchlight’s cell-free DNA platform offers a fundamentally different approach to DNA manufacturing—enabling the rapid, scalable, and high-quality production of enzymatically produced DNA for advanced therapies. At the core of this…
Read More
Touchlight’s Chief Scientific Officer, Dr. Jill Makin, discusses how the rapid evolution of advanced therapeutics is reshaping the industry, and why cell‑free DNA is has emerged as a foundational technology…
Read More
As cell and gene therapy scales, DNA choice matters. Learn the advantages of cell‑free DNA vs pDNA in this Q&A with Touchlight’s CSO.
Read More
This application note evaluates the in vivo performance of Touchlight’s doggybone DNA™ (dbDNA™) compared with conventional plasmid DNA when delivered using Sartorius Polyplus non‑viral delivery reagents. The study investigates how…
Read More
Explore how cell‑free DNA z‑dbDNA™ offers a faster, more flexible alternative to plasmid DNA for making RNA vaccines and therapies.
Read More
As cell and gene therapy scales, DNA choice matters. Learn the advantages of cell‑free DNA vs pDNA in this Q&A with Touchlight’s CSO.
Read More
This application note presents a comparative study of enzymatically manufactured doggybone DNA™ (dbDNA™) versus traditional plasmid DNA (pDNA) for lentiviral vector (LVV) production, using the FuGENE® 4K transfection reagent. The…
Read More
Discover how Touchlight’s novel circular DNA architectures—mbDNA™, sscDNA, hsscDNA, and dscDNA—enable precise, efficient gene insertion for next‑generation gene editing and non‑viral gene therapy.
Read More
This application note presents an independent cost-of-goods (COG) analysis conducted by Decisional Point Limited to evaluate the financial impact of switching from plasmid DNA (pDNA) to Touchlight’s enzymatically produced dbDNA™…
Read More
